This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
egfr
EGFR
ErbB1/HER1 receptor tyrosine kinase; EGF binding activates RAS-ERK, PI3K-Akt, and STAT3. Mutated or amplified in NSCLC, glioblastoma, HNSCC, and CRC. Targeted by gefitinib/erlotinib (EGFR-mutant NSCLC) and cetuximab (KRAS-WT CRC, HNSCC); osimertinib overcomes T790M resistance.
Entry Metadata
| Field | Value |
|---|---|
| ID | egfr |
| Name | EGFR |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137. · PubMed 11252954
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. · PubMed 15118073
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957. · PubMed 19692680